Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE-CRC-03 in previously treated metastatic colorectal cancer
NL-OMON61368Phase 3Not yet recruiting
- Sponsor
- Merck KGaA
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of precemtabart tocentecan in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON61368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61368.